Patents by Inventor Laurent Pradier

Laurent Pradier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transgenic animals exhibiting major disorders related to Alzheimer's disease
    Publication number: 20050076400
    Abstract: The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease.
    Type: Application
    Filed: October 1, 2004
    Publication date: April 7, 2005
    Applicant: Aventis Pharma S. A.
    Inventors: Caty Casas Louzao, Patrick Benoit, Laurent Pradier, Gunter Tremp, Jean-Michel Itier, Veronique Blanchard-Bregeon
  • Method for detecting Alzheimer's disease
    Publication number: 20050003417
    Abstract: Methods for the diagnosis or for the prognosis of Alzheimer's disease in an individual. Said method comprises at least one step of detection of the presence or absence of the minor allele of the rs908832 polymorphism of the ABCA2 gene. The presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene indicates that the individual may be suffering from Alzheimer's disease or else exhibits an increased risk of developing Alzheimer's disease.
    Type: Application
    Filed: June 17, 2004
    Publication date: January 6, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Sandrine Mace, Sylvain Ricard, Emmanuelle Cousin, Laurent Pradier, Jesus Benavides, Jean-Francois Deleuze
  • Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
    Publication number: 20040224409
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for brain-derived neurotrophic factor (BDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: December 23, 2003
    Publication date: November 11, 2004
    Inventors: Laurent Pradier, Pascal Barneoud, Pia Delaere, Michel Perricaudet, Emmanuelle Vigne
  • Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein
    Publication number: 20040214763
    Abstract: The present invention relates to a method for determining the ability of a compound to modify the interaction between parkin and the p38 protein, and in particular to a method for screening for or detecting compounds intended for the prevention and/or treatment of neurodegenerative pathological conditions.
    Type: Application
    Filed: July 18, 2003
    Publication date: October 28, 2004
    Applicants: Aventis Pharma, S.A., L'Institue Nat'l Santa Recherche Medicale
    Inventors: Olga Corti, Cornelia Hampe, Alexis Brice, Laurent Pradier, Thomas Rooney, Alain Fournier
  • Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
    Publication number: 20040138145
    Abstract: The subject of the invention is the application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of Alzheimer's disease, where appropriate, in combination with an HMG-CoA reductase inhibitor, a cholesterol uptake inhibitor, a cholesterol synthesis inhibitor or an APP secretase inhibitor.
    Type: Application
    Filed: December 12, 2003
    Publication date: July 15, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Thierry Canton, Laurent Pradier, Jesus Benavides, Hubert Heuer, Hans-Ludwig Schaefer
  • Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the &bgr;-amyloid peptide
    Patent number: 6653088
    Abstract: Provided herein are novel peptide and nucleotide sequences, their pharmaceutical use, as well as novel polypeptides capable of inhibiting at least partially the interaction between presenilin 1 or presenilin 2 and the &bgr;-amyloid peptide precursor or a &bgr;-amyloid peptide; also provided are in vitro tests and methods for detecting molecules and in particular, molecules capable of inhibiting said interaction.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: November 25, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Christian Czech, Luc Mercken, Laurent Pradier, Soline Reboul-Becquart
  • Compositions which can be used for regulating the activity of parkin
    Publication number: 20020155577
    Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
    Type: Application
    Filed: February 20, 2001
    Publication date: October 24, 2002
    Inventors: Hana Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Francoise Rosier-Montus, Olga Corti